Barclays Gets Bullish On US Biotechnology Sector (BBH)
More News related to ACAD
- ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 8, 2010
- Osteologix Announces Financing
- Acadia Pharmaceuticals (ACAD) Tops Q3 EPS by 1c
- ACADIA Pharma (ACAD) to Cut Workforce by 50%
- Unusual 11 Mid-Day Movers 10/06: FONR, ICTG, ACAD, AVCT Higher; MNKD, VRNMD, ARP, PPD Lower
More News related to AMGN
- Denosumab Demonstrated Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Prostate Cancer Patients With Bone Metastases
- Amgen (AMGN) March put volatility at 24, June at 30 into data
- Dempsey Challenge Participant Registration Officially Open
- Liberty Analytics Co. Initiates Independent Research Coverage on Amgen
- Amgen Donates $615,000 to Support International Medical Corps' Haiti Earthquake Disaster Relief Efforts
More News related to ARNA
- Pharmaceutical Stock Alert Arena Pharmaceuticals Issued by Beacon Equity
- Arena Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
- Rodman & Renshaw Upgrades Arena Pharmaceutical (ARNA) to Market Perform
- Arena Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
- After-Hours Movers 12/23: MRM, BQI, SLGN Higher; ARNA Lower
More News related to Upgrades
- Soleil Securities Upgrades Zebra Technologies (ZBRA) to Gradually Accumulate; Valuation Call
- UBS Issues Intraday Upgrade on Cimarex Energy (XEC)
- Boenning & Scattergood Upgrades Equinix (EQIX) to Outperform
- Avondale Partners Upgrades ADC Telecommunications (ADCT) to Market Outperform
- Johnson Rice Upgrades Pool Corp (POOL) to Overweight
Biotech HOLDRs (NYSE: BBH) is seeing some upside action today after the biotech industry received its second major upgrade in the past few weeks. The ETF is up 1% today.
Today, Barclays upgraded the US Biotechnology sector from Neutral to Positive, citing valuation and saying they see significant opportunity for the group into 2nd-half of 2009.
With the sector call, the firm also upgraded Biogen Idec (Nasdaq: BIIB) from Underweight to Equal Weight and raised its price target to $52.
The firm's top rated biotech picks in the sector include Amgen (Nasdaq: AMGN), Celgene (Nasdaq: CELG), Genzyme (Nasdaq: GENZ), Cephalon (Nasdaq: CEPH), Acadia (Nasdaq: ACAD), Arena (Nasdaq: ARNA), Rigel (Nasdaq: RIGL), Array (Nasdaq: ARRY), Onyx (Nasdaq: ONXX), Isis (Nasdaq: ISIS), Regeneron (Nasdaq: REGN)
Earlier in the month, Goldman Sachs upgraded U.S. Large Cap Biotechs to Neutral.
Related Categories
UpgradesStocks Mentioned
+0.03
-0.25Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
